CAS 874819-74-6

Fosfato de Toceranib

Descripción:

Fosfato de Toceranib es un fármaco de molécula pequeña utilizado principalmente en medicina veterinaria, particularmente para el tratamiento de ciertos tipos de cáncer en perros. Es un inhibidor de la tirosina quinasa que se dirige a vías específicas involucradas en el crecimiento tumoral y la angiogénesis, lo que lo hace efectivo contra tumores que expresan el receptor del factor de crecimiento endotelial vascular (VEGF). El compuesto es conocido por su capacidad para inhibir la actividad de varias tirosina quinasas receptoras, que juegan un papel crucial en la señalización celular relacionada con el crecimiento y la proliferación. Fosfato de Toceranib se administra típicamente por vía oral y se absorbe bien en el tracto gastrointestinal. Su farmacocinética indica una vida media moderada, lo que permite una dosificación una vez al día en entornos clínicos. Los efectos secundarios comunes pueden incluir trastornos gastrointestinales, letargo y cambios en los recuentos de células sanguíneas, lo que requiere monitoreo durante el tratamiento. En general, el fosfato de toceraib representa un avance significativo en el manejo de tumores caninos, proporcionando una opción terapéutica dirigida que puede mejorar los resultados para los animales afectados.

Sinónimos:

• 5-[(Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl]-2,4-dimethyl-N-(2-pyrrolidin-1-ylethyl)-1H-pyrrole-3-carboxamide,phosphoric acid
• 5-[(Z)-(5-Fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl]-2,4-dimethyl-N-[2-(1-pyrrolidinyl)ethyl]-1H-pyrrole-3-carboxamide phosphate

Toceranib phosphate

CAS: 874819-74-6

Fórmula: C₂₂H₂₈FN₄O₆P

Pureza: 98%

Forma y color: Solid

Peso molecular: 494.4531

Ref: IN-DA00GU75

Toceranib Phosphate

CAS: 874819-74-6

Toceranib Phosphate

Pureza: ≥98%

Peso molecular: 494.46g/mol

Ref: 54-PC109154

Toceranib Phosphate

CAS: 874819-74-6

Toceranib Phosphate

Pureza: ≥98%

Peso molecular: 494.45g/mol

Ref: 54-BUP11203

Toceranib Phosphate

CAS: 874819-74-6

Toceranib Phosphate (SU11654 phosphate), is a selective inhibitor of the tyrosine kinase activity of several members of the split kinase RTK family.

Fórmula: C₂₂H₂₈FN₄O₆P

Pureza: 98.56%

Forma y color: Solid

Peso molecular: 494.45

Ref: TM-T7394

Toceranib Phosphate

Producto controlado

CAS: 874819-74-6

Applications Toceranib Phosphate is a useful compound in the treatment of chemotherapy-induced diarrhea.
References Conte, L. A.: U.S. Pat. Appl. Publ. (2020), US 20200345687 A1

Fórmula: C₂₂H₂₅FN₄O₂·H₃PO₄

Forma y color: Neat

Peso molecular: 396.47 + (97.99)

Ref: TR-T525503

Toceranib phosphate - Bio-X ™

Producto controlado

CAS: 874819-74-6

Toceranib phosphate is a receptor tyrosine kinase inhibitor. Toceranib phosphate has been shown to be effective in the treatment of skin cancer and other types of cancer, including lung cancer and breast cancer. It is approved in the US as a treatment for canine mastocytoma (mast cell tumours).

Fórmula: C₂₂H₂₅FN₄O₂·H₃O₄P

Pureza: Min. 95%

Forma y color: Powder

Peso molecular: 494.45 g/mol

Ref: 3D-BT162330

Toceranib phosphate

Producto controlado

CAS: 874819-74-6

Toceranib phosphate is a tyrosine kinase inhibitor that is used to treat a variety of cancers. It has been shown to be an effective treatment for solid tumours, such as lung cancer and renal cell carcinoma. Toceranib has also been shown to have anti-angiogenic properties, which may contribute to its antitumor response. One study found that the drug is cleared by the liver and eliminated by the kidneys, with a half-life of approximately 15 hours. A phase II clinical trial found that Toceranib was well tolerated in patients with metastatic breast cancer who had previously been treated with anthracyclines and taxanes. The most common adverse effects were diarrhea (in 8% of subjects), hypertension (6%), and nausea (3%).

Fórmula: C₂₂H₂₅FN₄O₂•H₃O₄P

Pureza: 90%

Forma y color: Powder

Peso molecular: 494.45 g/mol

Ref: 3D-FT104292